Simulect Injection 20 mg 1 Vial
Condition : New
0
From UAE
To United States
in 5-10 days
Description
Simulect (Basiliximab) is a monoclonal antibody used as an immunosuppressant in organ transplantation. It is particularly effective in preventing acute rejection of transplanted kidneys in patients undergoing renal transplantation. Simulect is typically administered alongside other immunosuppressive therapies to enhance the chances of transplant success while minimizing the risk of rejection.
How It Works
Simulect (Basiliximab) works by specifically targeting and binding to the CD25 subunit of the interleukin-2 (IL-2) receptor on activated T cells. Here’s a more detailed breakdown of its mechanism of action:- Inhibition of IL-2 Activity: Interleukin-2 is a crucial growth factor for T cells, which play a key role in the body’s immune response. By binding to the CD25 receptor, Simulect prevents IL-2 from activating T cells, thereby inhibiting their proliferation and activity.
- Reduction of Immune Response: By blocking the action of IL-2, Simulect reduces the immune system’s response to the transplanted organ, thus lowering the risk of acute rejection.
- Selective Targeting: Unlike traditional immunosuppressive drugs that can broadly suppress the immune system, Simulect is designed to selectively inhibit only those T cells that are activated by the transplant, making it a more targeted therapy.
Indications
Simulect is indicated for:- Prevention of Acute Rejection: It is used for the prevention of acute rejection in adult and pediatric patients receiving kidney transplants. Simulect is administered during the perioperative period, specifically given before transplantation and then again after the transplant procedure.
- Combined Immunosuppressive Therapy: Simulect is typically used in conjunction with other immunosuppressive agents, such as corticosteroids and calcineurin inhibitors, to provide a comprehensive approach to preventing organ rejection.
Side Effects
Simulect can cause a variety of side effects, which may include: Common Side Effects:- Nausea and Vomiting
- Fever and Chills
- Injection Site Reactions: Such as pain, redness, or swelling at the injection site.
- Headache
- Increased Risk of Infections: As a result of immunosuppression.
- Anaphylactic Reactions: Rarely, patients may experience severe allergic reactions, which could include difficulty breathing, swelling of the face or throat, and hives.
- Cytokine Release Syndrome: Symptoms can include fever, fatigue, and flu-like symptoms, occurring due to the immune system’s response to the drug.
- Severe Infections: Increased susceptibility to infections due to immunosuppression, which may lead to serious complications.
Contraindications
Simulect is contraindicated in:- Hypersensitivity: Patients with a known hypersensitivity to basiliximab or any component of the formulation should avoid this medication.
- Active Infections: The use of Simulect in patients with active infections should be approached with caution, as the immunosuppressive effect can worsen these conditions.
- Pregnancy and Lactation: Simulect should only be used in pregnant or breastfeeding women if clearly needed, and the risks versus benefits should be thoroughly evaluated.
Pricing Table (in Different Countries)
The price of Simulect Injection 20 mg can vary depending on the country and healthcare system. Here’s a comparison of prices in various regions.Simulect (Basiliximab) 20 mg Price Comparison
Country | Price (USD) | Reference |
---|---|---|
United States | $3,000 per vial | GoodRx |
United Kingdom | £2,200 per vial | NICE BNF |
Canada | CAD $3,500 per vial | DrugBank |
Australia | AUD $4,000 per vial | PBS Australia |
Germany | €2,600 per vial | G-BA Germany |
Top 5 Global Brands
- Roche: The original developer of Simulect, Roche is a global leader in biotechnology and pharmaceuticals, particularly in immunology and oncology.
- Genentech: A subsidiary of Roche, Genentech focuses on developing targeted therapies and has a strong portfolio in immunosuppressive drugs.
- Bristol-Myers Squibb: This company is known for its advancements in immunology and oncology, contributing significantly to transplant medicine.
- Amgen: Amgen is a biotechnology company that develops innovative therapies, including those for transplant rejection.
- Novartis: A major player in the pharmaceutical industry, Novartis has developed a variety of immunosuppressive therapies and continues to research new treatments for organ transplantation.